Correcting oral contraceptive pharmacokinetic alterations due to obesity: A randomized controlled trial

Contraception

Volumn 90, Issue 5, 2014, Pages 550-556

  Edelman, Alison B ^a   Cherala, Ganesh ^a,b   Munar, Myrna Y ^b   McInnis, Martha ^a   Stanczyk, Frank Z ^c   Jensen, Jeffrey T ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON STATE UNIVERSITY   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

BMI; Continuous dosing; Drug levels; Hormonal contraception

Indexed keywords

ETHINYLESTRADIOL; HORMONE; LEVONORGESTREL; ORAL CONTRACEPTIVE AGENT; PLACEBO;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG ELIMINATION; FEMALE; HORMONAL CONTRACEPTION; HUMAN; MAXIMUM PLASMA CONCENTRATION; OBESITY; ORAL CONTRACEPTION; OVARY FOLLICLE; OVULATION; PHARMACODYNAMICS; PHARMACOLOGICAL PARAMETERS; PILL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SERUM; STEADY STATE; BLOOD; YOUNG ADULT;

ADULT; CONTRACEPTIVES, ORAL, COMBINED; ETHINYL ESTRADIOL; FEMALE; HUMANS; LEVONORGESTREL; OBESITY; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84916930635     PISSN: 00107824     EISSN: 18790518     Source Type: Journal    
DOI: 10.1016/j.contraception.2014.06.033     Document Type: Article

References (20)

1. Edelman AB, Carlson NE, Cherala G, et al. Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic-pituitary-ovarian activity. Contraception 2009;80:119-27.
2. Edelman AB, Cherala G, Stanczyk FZ. Metabolism and pharmacokinetics of contraceptive steroids in obese women: a review. Contraception 2010;82:314-23.
3. Abdel-Rahman SM, Kauffman RE. The integration of pharmacokinetics and pharmacodynamics: understanding dose-response. Annu Rev Pharmacol Toxicol 2004;44:111-36.
4. Westhoff CL, Torgal AT, Mayeda ER, Shimoni N, Stanczyk FZ, Pike MC. Predictors of noncompliance in an oral contraceptive clinical trial. Contraception 2012;85(5):465-9.
5. Contraceptive Use in the United States. July 2012. Accessed 9/28/2012, at http://www.guttmacher.org/pubs/fb_contr_use.html.
6. Pinter B. Continuation and compliance of contraceptive use. Eur J Contracept Reprod Health Care 2002;7:178-83.
7. Edelman AB, Cherala G, Munar MY, et al. Prolongedmonitoring of ethinyl estradiol and levonorgestrel levels confirms an altered pharmacokinetic profile in obese oral contraceptives users. Contraception 2012;87:220-6.
8. Westhoff CL, Torgal AH, Mayeda ER, et al. Ovarian suppression in normal-weight and obese women during oral contraceptive use: a randomized controlled trial. Obstet Gynecol 2010;116:275-83.
9. World Health Organization. WHO laboratory manual for the examination of human sperm and sperm-cervical mucus interaction. Cambridge: Cambridge University Press; 1992.
10. Nicolau DP. Predicting antibacterial response from pharmacodynamic and pharmacokinetic profiles. Infection 2001;29(Suppl 2):11-5.
11. Westhoff CL, Torgal AH, Mayeda ER, Pike MC, Stanczyk FZ. Pharmacokinetics of a combined oral contraceptive in obese and normal-weight women. Contraception 2010;81:474-80.
12. Croxatto HB. NORPLANT: levonorgestrel-releasing contraceptive implant. Ann Med 1993;25:155-60.
13. Levonorgestrel Fotherby K. Clinical pharmacokinetics. Clin Pharmacokinet 1995;28:203-15.
14. Fotherby K. Pharmacokinetics of gestagens: some problems. Am J Obstet Gynecol 1990;163:323-8.
15. Sambol NC, Harper CC, Kim L, Liu CY, Darney P, Raine TR. Pharmacokinetics of single-dose levonorgestrel in adolescents. Contraception 2006;74:104-9.
16. Hautanen A. Synthesis and regulation of sex hormone-binding globulin in obesity. Int J Obes Relat Metab Disord 2000;24(Suppl 2):S64-70.
17. Glasier A, Cameron ST, Blithe D, et al. Can we identify women at risk of pregnancy despite using emergency contraception? Data from randomized trials of ulipristal acetate and levonorgestrel. Contraception 2011;84:363-7.
18. Dinger J, Minh TD, Buttmann N, Bardenheuer K. Effectiveness of oral contraceptive pills in a large U.S. cohort comparing progestogen and regimen. Obstet Gynecol 2011;117:33-40.
19. Willis SA, Kuehl TJ, Spiekerman AM, Sulak PJ. Greater inhibition of pituitary-ovarian axis in oral contraceptive regimens with a shortened hormone-free interval. Contraception 2006;74:100-3.
20. van Heusden AM, Fauser BCJM. Residual ovarian activity during oral steroid contraception. Hum Reprod Update 2002;8:345-58.